1. Scrip
  2. >>Business

Roche Bonds With Monte Rosa To Degrade Molecular Glues

Deal Expands Reach Of Protein Degradation Platform

 
• By Mandy Jackson

Deal Snapshot: Monte Rosa Therapeutics received $50m up front and may earn more than $2bn in milestone fees from Roche for molecular glue degraders to treat cancer and neurological diseases. 

Collaboration and related terms on gears
Monte Rosa and Roche will collaborate across multiple targets • Source: Shutterstock

Who: Monte Rosa Therapeutics/Roche

What: Monte Rosa will discover molecular glue degraders with its QuEEN platform and Roche will advance preclinical and clinical development of the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business